HAMBURG, Germany and
MENLO PARK, Calif., April 21, 2020 /PRNewswire/ -- Indivumed
GmbH ("Indivumed") and Personalis, Inc. (Nasdaq: PSNL) today
announced that the two companies have entered into a collaboration
in the field of personalized oncology. The partnership seeks to
enable novel discoveries in cancer biology by pairing IndivuType,
Indivumed's multiomics cancer database, with genome and
transcriptome-level data from thousands of samples using
Personalis' advanced cancer genomics technology.
"Genomics and transcriptomics play a crucial role in truly
understanding cancer biology," said Dr. Hartmut Juhl, Indivumed CEO and founder. "Adding
Personalis' technology to the IndivuType multiomics profile will
enable relevant discoveries in our collaborations with pharma and
biotech and further our mission to advance precision oncology."
The IndivuType database provides high-quality samples that
enable analysis beyond genomics to include transcriptomics,
proteomics, phosphoproteomics and immunophenotyping in combination
with clinical and outcome data that makes it a powerful resource
for the cancer community. Pairing these high-quality samples with
Personalis' innovative and robust solutions for comprehensive tumor
genomics characterization has the potential to provide deeper
insights into oncology therapeutics.
"Working with Indivumed on this program will allow us to deliver
broad, more comprehensive genomic sequencing for cancer that can
ultimately fuel drug discovery and development," said John West, CEO of Personalis. "Pairing
Indivumed's leading position as a premier quality clinical cancer
biobank with our extensive genomics experience will result in one
of the most comprehensive multiomics cancer databases in the world.
More importantly we feel these databases will provide the insights
needed to drive precision medicine in oncology. This new offering
leverages Personalis' extensive whole genome sequencing experience,
including laboratory automation and data systems developed for the
U.S. Department of Veterans Affairs ("VA") for the VA Million
Veterans Program, and our expertise in processing tumor samples as
part of large-scale oncology translational research projects with
our biopharma partners."
About Indivumed
Indivumed is a science-led,
integrated global oncology company. Our platform is an enabler for
the next generation of precision oncology through our proprietary
multiomics cancer database and customized data analytics,
underpinned by our global network of affiliated clinics with
gold-standard quality of biospecimens. Through our unique platform,
we offer specialized products and services that support our
customers in biomarker and target discovery, drug development,
clinical trials, individualized therapy and more. More information
at www.indivumed.com
About Personalis, Inc.
Personalis,
Inc. is a growing cancer genomics company transforming the
development of next-generation therapies by providing more
comprehensive molecular data about each patient's cancer and immune
response. The Personalis ImmunoID NeXT Platform™ is designed to
adapt to the complex and evolving understanding of cancer,
providing its biopharmaceutical customers with information on all
of the approximately 20,000 human genes, together with the immune
system, from a single tissue sample. Personalis also
provides genomic information to the VA Million Veterans Program as
part of their goal to sequence over a million veteran genomes.
The Personalis Clinical Laboratory is GxP aligned as
well as CLIA'88-certified and CAP-accredited. For more information,
please visit www.personalis.com and follow Personalis on Twitter
(@PersonalisInc).
Forward-Looking Statements
This press release
contains or may imply "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. For example,
forward-looking statements include statements regarding potential
positive outcomes resulting from the collaboration of Personalis
and Indivumed, such as the ability of the collaboration to yield
novel discoveries. These forward-looking statements are subject to
risks and uncertainties, including those discussed
in Personalis' filings with the Securities and
Exchange Commission (SEC), including in the "Risk Factors" and
"Management's Discussion and Analysis of Financial Condition and
Results of Operations" sections of the Company's most recently
filed periodic report on Form 10-K and subsequent filings and in
the documents incorporated by reference therein. Except as
otherwise required by law, Personalis disclaims any
intention or obligation to update or revise any forward-looking
statements, which speak only as of the date hereof, whether as a
result of new information, future events or circumstances or
otherwise.
Contact for Indivumed:
Patrick
Renegar
W: 703-519-1600 Ext. 104
prenegar@livewiredc.com
Contacts for Personalis, Inc.
Investor Relations
Contact for Personalis:
Caroline
Corner
investors@personalis.com
415-202-5678
Media Contact for Personalis:
Jennifer Havlek
pr@personalis.com
www.personalis.com
650-752-1300
View original content to download
multimedia:http://www.prnewswire.com/news-releases/indivumed-personalis-partner-to-enhance-genomic-sequencing-capabilities-301043849.html
SOURCE Indivumed